Biomarkers – Multimedia

While depleting abundant proteins can facilitate the detection of low-concentration biomarkers, such methods can be labor-intensive, costly and can result in sample loss. Discover how parallel accumulation, serial elution and fragmentation (PASEF) can support researchers to achieve accurate large-scale plasma proteomics.

A new study identifies a set of biomarkers that could help clinicians to predict whether pancreatic cysts will remain benign or develop into cancer.

While most protein assays excel in one or two areas, the SomaScan Assay is the first and only platform that can measure 7,000 proteins from a 55-µL sample – covering more biological pathways than any other proteomic assay.

The SomaScan Assay is an ideal high throughput platform for identifying proteins that may be involved in disease pathology, as it offers a highly sensitive method of quantifying proteins in different biologic fluids such as serum, plasma, urine and cerebrospinal fluid.

Developed for performance in human serum and plasma, the SomaScan Assay v4.1 can measure approximately 7,000 unique human protein analytes in small volumes of biological samples.

The Ella instrument by Bio-Techne automates every step of the immunoassay workflow, helping to minimize user error while ensuring highly precise and reproducible results.

Speaking at ‘Advances in Proteomics & Metabolomics’ 2022, Erik Johnson from Emory University, presented their talk on proteomics in Alzheimer’s disease.

Spatial biology relies on validated reagents to map proteins in tissue. While immunofluorescence is widely used, there are no universal guidelines for antibody validation, posing challenges for accuracy and reproducibility in research.

Rather than choosing between the detail of single-cell RNA sequencing and the in situ capabilities of conventional immunohistochemistry, spatial phenotyping allow you to visualize and quantify dozens of biomarkers in a single tissue sample while maintaining cellular and sub-cellular detail.

Only a small amount of cell-free DNA (cfDNA) can be found in circulation, therefore efficient and highly sensitive technologies such as next-generation sequencing (NGS) are typically being used to detect this biomarker.